European Heart Journal Advance Access published online on September 21, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi495
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Cardiology, London Chest Hospital, Bonner Road, London E2 9JX, UK
* To whom correspondence should be addressed. Aims The anti-anginal efficacy and safety of ranolazine in diabetic and non-diabetic patients included in the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial (JAMA 2004;291:309) were studied. Glycaemic control was also assessed in CARISA and its long-term open-label extension study. Methods and results Patients with chronic angina enrolled in CARISA (189 with diabetes, 634 without diabetes) on background atenolol, diltiazem, or amlodipine therapy were randomized to placebo, ranolazine 750 or 1000 mg twice daily for 12 weeks, during which exercise tolerance, angina frequency, nitroglycerin usage, glucose, HbA1c, and lipids were measured. Patients completing the randomized study could enroll in an ongoing open-label extension study and were evaluated every 3 months. Ranolazine produced similar improvements in exercise parameters, nitroglycerin use, and angina frequency in diabetic and non-diabetic patients. Adverse events were similar between groups. Fasting glucose and lipids remained unaltered in diabetic patients after 12 weeks of therapy. In a post hoc analysis, ranolazine 750 and 1000 mg reduced HbA1c vs. placebo by 0.48 ± 0.18% (P = 0.008) and 0.70 ± 0.18% (P = 0.0002), respectively; the HbA1c levels appeared to remain unchanged over time during long-term therapy. Conclusion Anti-anginal efficacy and safety of ranolazine for angina were similar between diabetic and non-diabetic patients. Ranolazine significantly improved glycaemic control in diabetic patients.
Received January 31, 2005
Revised July 19, 2005
Accepted August 19, 2005
Clinical research
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
2 St Louis University Health Services Center, St Louis, MO, USA
3 CV Therapeutics Inc., Palo Alto, CA, USA
Adam D. Timmis, E-mail: timmis{at}1ch.demon.co.uk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. H. Opie and J. Knuuti The adrenergic-Fatty Acid load in heart failure. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1637 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Morrow, B. M. Scirica, B. R. Chaitman, D. K. McGuire, S. A. Murphy, E. Karwatowska-Prokopczuk, C. H. McCabe, E. Braunwald, and for the MERLIN-TIMI 36 Investigators Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial Circulation, April 21, 2009; 119(15): 2032 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Cooper-DeHoff, M. A. Pacanowski, and C. J. Pepine Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J. Am. Coll. Cardiol., February 3, 2009; 53(5 Suppl): S28 - S34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Zerumsky and B. F. McBride Ranolazine in the management of chronic stable angina Am. J. Health Syst. Pharm., December 1, 2006; 63(23): 2331 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Chaitman Ranolazine for the Treatment of Chronic Angina and Potential Use in Other Cardiovascular Conditions Circulation, May 23, 2006; 113(20): 2462 - 2472. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Bassand Clinical implications of inhibition of the late sodium current: ranolazine Eur. Heart J. Suppl., February 1, 2006; 8(suppl_A): A14 - A19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Cooper-DeHoff and C. J. Pepine Ranolazine is associated with cardiovascular and metabolic improvement: a win-win for patients with diabetes Eur. Heart J., January 1, 2006; 27(1): 5 - 6. [Full Text] [PDF]
|
|